{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:54:41Z","timestamp":1786996481821,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Applied Health Research Question"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.sapharm.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T19:38:39Z","timestamp":1585769919000},"page":"257-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacist interventions for persons with intellectual disabilities: A scoping review"],"prefix":"10.1016","volume":"17","author":[{"given":"Catherine","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Wen","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2020.03.009_bib1","author":"American Association on Intellectual"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1468-3148.2005.00240.x","article-title":"Understanding health disparities and inequities faced by individuals with intellectual disabilities","volume":"18","author":"Ouellette\u2010Kuntz","year":"2005","journal-title":"J Appl Res Intellect Disabil"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s40474-016-0085-7","article-title":"Systematic review of the prevalence and incidence of intellectual disabilities: current trends and issues","volume":"3","author":"McKenzie","year":"2016","journal-title":"Curr Dev Disord Reports"},{"issue":"July","key":"10.1016\/j.sapharm.2020.03.009_bib4","first-page":"1","article-title":"Healthcare for persons with intellectual and developmental disability in the community","volume":"2","author":"Ervin","year":"2014","journal-title":"Front Public Heal"},{"issue":"4","key":"10.1016\/j.sapharm.2020.03.009_bib5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s11096-015-0113-4","article-title":"Pharmacists' medicines-related interventions for people with intellectual disabilities: a narrative review","volume":"37","author":"O'Dwyer","year":"2015","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2788.2008.01141.x","article-title":"The documentation of health problems in relation to prescribed medication in people with profound intellectual and multiple disabilities","volume":"53","author":"van der Heide","year":"2009","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1741-1130.2010.00248.x","article-title":"Major health risks in aging persons with intellectual disabilities: an overview of recent studies","volume":"7","author":"Haveman","year":"2010","journal-title":"J Pol Pract Intellect Disabil"},{"key":"10.1016\/j.sapharm.2020.03.009_bib8","series-title":"Atlas on the Primary Care of Adults with Developmental Disabilities in Ontario","author":"Lunsky","year":"2013"},{"issue":"5","key":"10.1016\/j.sapharm.2020.03.009_bib9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.ridd.2013.02.005","article-title":"Prescription errors in older individuals with an intellectual disability: prevalence and risk factors in the Healthy Ageing and Intellectual Disability Study","volume":"34","author":"Zaal","year":"2013","journal-title":"Res Dev Disabil"},{"issue":"6","key":"10.1016\/j.sapharm.2020.03.009_bib10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1108\/AMHID-05-2013-0032","article-title":"Use of PRN medication in people with intellectual disabilities","volume":"7","author":"Delafon","year":"2013","journal-title":"Adv Ment Health Intellect Disabil"},{"issue":"4","key":"10.1016\/j.sapharm.2020.03.009_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jar.12183","article-title":"Structured medication review to improve pharmacotherapy in people with intellectual disability and behavioural problems","volume":"29","author":"Scheifes","year":"2016","journal-title":"J Appl Res Intellect Disabil"},{"issue":"7","key":"10.1016\/j.sapharm.2020.03.009_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2788.2010.01275.x","article-title":"Use of antipsychotic drugs in individuals with intellectual disability (ID) in The Netherlands: prevalence and reasons for prescription","volume":"54","author":"de Kuijper","year":"2010","journal-title":"J Intellect Disabil Res"},{"issue":"10","key":"10.1016\/j.sapharm.2020.03.009_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/jir.12391","article-title":"Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland","volume":"61","author":"O'Dwyer","year":"2017","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3484","article-title":"Psychotropic medication use in adolescents with intellectual disability living in the community","volume":"23","author":"Doan","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.sapharm.2020.03.009_bib15","article-title":"Antipsychotic medication for challenging behaviour in people with learning disability","volume":"3","author":"Brylewski","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.sapharm.2020.03.009_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/2042098618782785","article-title":"Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research","volume":"9","author":"O'Dwyer","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1468-3148.2000.00010.x","article-title":"A study of the knowledge that people with intellectual disabilities have of their prescribed medication","volume":"13","author":"Arscott","year":"2000","journal-title":"J Appl Res Intellect Disabil"},{"issue":"4","key":"10.1016\/j.sapharm.2020.03.009_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1211\/ijpp.14.4.0006","article-title":"Perspectives on the role of the community pharmacist in the provision of healthcare to people with intellectual disabilities: exploration of the barriers and solutions","volume":"14","author":"Blasi","year":"2006","journal-title":"Int J Pharm Pract"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/jar.12117","article-title":"Identifying training needs for mainstream healthcare professionals, to prepare them for working with individuals with intellectual disabilities: a systematic review","volume":"28","author":"Hemm","year":"2015","journal-title":"J Appl Res Intellect Disabil"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2788.2004.00483.x","article-title":"People with intellectual disability and their health problems: a review of comparative studies","volume":"48","author":"Jansen","year":"2004","journal-title":"J Intellect Disabil Res"},{"issue":"9","key":"10.1016\/j.sapharm.2020.03.009_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1365-2788.2011.01439.x","article-title":"The impact of living arrangements and deinstitutionalisation in the health status of persons with intellectual disability in Europe","volume":"55","author":"Martinez-Leal","year":"2011","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7870\/cjcmh-2009-0014","article-title":"Deinstitutionalization of people with developmental disabilities: a review of the literature","volume":"28","author":"Lemay","year":"2009","journal-title":"Can J Community Ment Health"},{"issue":"9","key":"10.1016\/j.sapharm.2020.03.009_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0184390","article-title":"Medication and supplement use in older people with and without intellectual disability: an observational, cross-sectional study","volume":"12","author":"Peklar","year":"2017","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1715163515581342","article-title":"CphA national survey Canadians trust pharmacists","volume":"148","author":"Doucet","year":"2015","journal-title":"Can Pharm J"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11096-018-0771-0","article-title":"Hassles with medication management perceived by caregivers of adults who have intellectual or developmental disabilities","volume":"41","author":"Erickson","year":"2019","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"issue":"7","key":"10.1016\/j.sapharm.2020.03.009_bib27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2020.03.009_bib28","volume":"14","year":"2008"},{"key":"10.1016\/j.sapharm.2020.03.009_bib29","series-title":"Facts about Developmental Disabilities","year":"2018"},{"key":"10.1016\/j.sapharm.2020.03.009_bib30","series-title":"DSM-5 Fact Sheets: Intellectual Disability","year":"2013"},{"key":"10.1016\/j.sapharm.2020.03.009_bib31","series-title":"Behaviour and Learning Disabilities: Prevention and Interventions for People with Learning Disabilities Whose Behaviour Challenges: Methods, Evidence and Recommendations","author":"Challenging","year":"2015"},{"key":"10.1016\/j.sapharm.2020.03.009_bib32","series-title":"Valuing People - A New Strategy for Learning Disability for the 21st Century","author":"Department of Health and Social Care","year":"2001"},{"key":"10.1016\/j.sapharm.2020.03.009_bib33","series-title":"Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services","author":"Cipolle","year":"2012"},{"key":"10.1016\/j.sapharm.2020.03.009_bib34","series-title":"PNCE Classification for Drug Related Problems V8:03","year":"2019"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.2042-7174.2002.tb00593.x","article-title":"A classification system for issues identified in pharmaceutical care practice","volume":"10","author":"Krska","year":"2002","journal-title":"Int J Pharm Pract"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jamda.2014.12.013","article-title":"An international definition for \u201cnursing home","volume":"16","author":"Sanford","year":"2015","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.sapharm.2020.03.009_bib37","article-title":"WHO Consultative Group for the role of the pharmacist in the health care system","year":"1994"},{"key":"10.1016\/j.sapharm.2020.03.009_bib38","series-title":"Model Standard of Practice for Canadian Pharmacists","author":"National Association of Pharmacy Regulatory Authorities","year":"2009"},{"key":"10.1016\/j.sapharm.2020.03.009_bib39","series-title":"Canadian Pharmacy Services Framework","author":"Canadian Pharmacists Association and Canadian Association of Chain Drug stores","year":"2011"},{"key":"10.1016\/j.sapharm.2020.03.009_bib40","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHuge","year":"2012","journal-title":"Biochem Med"},{"issue":"4","key":"10.1016\/j.sapharm.2020.03.009_bib42","article-title":"Implementation of clinical pharmacy services: rationalizing drug therapy in a mental retardation facility","volume":"13","author":"Inoue","year":"1978","journal-title":"Hosp Formul"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib43","first-page":"70","article-title":"A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons","volume":"20","author":"Inoue","year":"1982","journal-title":"Ment Retard"},{"issue":"4","key":"10.1016\/j.sapharm.2020.03.009_bib44","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/j.1875-9114.1997.tb03758.x","article-title":"Impact of a pharmacist-based consult service on nutritional rehabilitation of nonambulatory patients with severe developmental disabilities","volume":"17","author":"Brown","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib45","first-page":"234","article-title":"Clinical pharmacy services in an intermediate care facility for the mentally retarded","volume":"29","author":"McKee","year":"1994","journal-title":"Hosp Pharm"},{"issue":"6","key":"10.1016\/j.sapharm.2020.03.009_bib46","first-page":"604","article-title":"Pharmacist impact on drug use in an institution for the mentally retarded","volume":"34","author":"Ellenor","year":"1977","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.sapharm.2020.03.009_bib47","article-title":"Medicines optimisation for paediatric patients with learning disability","volume":"103","author":"Joanne","year":"2018"},{"key":"10.1016\/j.sapharm.2020.03.009_bib48","first-page":"203","article-title":"Pharmaceutical care program in a service to people with disabilities","volume":"19","author":"Roca","year":"2012"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib49","first-page":"137","article-title":"Changes in psychotropic drug use in long-term residents of an ICF\/MR facility","volume":"96","author":"Hancock","year":"1991","journal-title":"Am J Ment Retard"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib50","first-page":"7","article-title":"Assuring the quality of the utilization of psychoactive medication by people with mental retardation and developmental disabilities by assessing dosages","volume":"3","author":"Brasi\u0107","year":"2000","journal-title":"Ger J Psychiatr"},{"issue":"11","key":"10.1016\/j.sapharm.2020.03.009_bib51","first-page":"827","article-title":"Implementation of a psychotropic drug review service in a mental retardation facility","volume":"20","author":"Marcoux","year":"1985","journal-title":"Hosp Pharm"},{"issue":"5","key":"10.1016\/j.sapharm.2020.03.009_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ajhp\/61.5.487","article-title":"Clinical pharmacology services: a pharmacist-based consulting service for the developmentally disabled","volume":"61","author":"Brahm","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sapharm.2020.03.009_bib53","first-page":"4","article-title":"Pharmacist independent prescriber working in a Community Learning Disability team-releasing psychiatry time and delivering STOMP","volume":"32","author":"Gerrard","year":"2018"},{"key":"10.1016\/j.sapharm.2020.03.009_bib54","first-page":"12","article-title":"Clinical pharmacist medication review of patients with learning disabilities: what types of interventions are made?","volume":"24","author":"Shaw","year":"2016"},{"issue":"Feb 4","key":"10.1016\/j.sapharm.2020.03.009_bib55","first-page":"158","article-title":"Pharmacists and community care in learning disabilities","volume":"254","author":"Vickers","year":"1995","journal-title":"Pharm J"},{"key":"10.1016\/j.sapharm.2020.03.009_bib56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ridd.2016.03.014","article-title":"Medication review using a Systematic Tool to Reduce Inappropriate Prescribing (STRIP) in adults with an intellectual disability: a pilot study","volume":"55","author":"Zaal","year":"2016","journal-title":"Res Dev Disabil"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib57","first-page":"327","article-title":"Medication review in patients with mental disabilities","volume":"39","author":"Gran\u00e5s","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.sapharm.2020.03.009_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1352\/1934-9556-54.6.412","article-title":"Issues in the medication management process in people who have intellectual and developmental disabilities: a qualitative study of the caregivers' perspective","volume":"54","author":"Erickson","year":"2016","journal-title":"Intellect Dev Disabil"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11096-015-0217-x","article-title":"Knowledge that people with intellectual disabilities have of their inhaled asthma medications: messages for pharmacists","volume":"38","author":"Davis","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.sapharm.2020.03.009_bib60","series-title":"Pharmacotherapy Analysis of Individuals with Intellectual Disability Residing in Community Settings","author":"Tessier","year":"2001"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jppi.12064","article-title":"Medication management in Belgian residential care facilities for individuals with intellectual disability: an observational study","volume":"11","author":"Joos","year":"2014","journal-title":"J Pol Pract Intellect Disabil"},{"issue":"9","key":"10.1016\/j.sapharm.2020.03.009_bib62","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4140\/TCP.n.2007.763","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in a group home setting","volume":"22","author":"Collins","year":"2007","journal-title":"Consult Pharm"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib63","first-page":"64","article-title":"Integrating clinical pharmacy service into the interdisciplinary team structure","volume":"20","author":"VanKrevelen","year":"1982","journal-title":"Ment Retard"},{"issue":"10","key":"10.1016\/j.sapharm.2020.03.009_bib64","first-page":"1671","article-title":"Effect of a consultant pharmacist on medication use in an institution of the mentally retarded","volume":"39","author":"Berchou","year":"1982","journal-title":"Am J Hosp Pharm"},{"issue":"11","key":"10.1016\/j.sapharm.2020.03.009_bib65","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1365-2788.2009.01212.x","article-title":"The effect of an intervention aimed at reducing errors when administering medication through enteral feeding tubes in an institution for individuals with intellectual disability","volume":"53","author":"Idzinga","year":"2009","journal-title":"J Intellect Disabil Res"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib66","first-page":"1","article-title":"With intellectual disabilities for a health promotion study","volume":"10","author":"Horner-johnson","year":"2014","journal-title":"Assessing"},{"issue":"4","key":"10.1016\/j.sapharm.2020.03.009_bib67","first-page":"254","article-title":"Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines","volume":"64","author":"Sullivan","year":"2018","journal-title":"Can Fam Physician"},{"issue":"suppl 2","key":"10.1016\/j.sapharm.2020.03.009_bib68","article-title":"Intellectual disability: definition, etiological factors, classification, diagnosis, treatment and prognosis","volume":"50","author":"Katz","year":"2008","journal-title":"Salud Publica Mex"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib69","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.chc.2017.03.001","article-title":"Intellectual disability and language disorder","volume":"26","author":"Marrus","year":"2017","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1741-1130.2010.00253.x","article-title":"Dementia in older adults with intellectual disabilities - epidemiology, presentation, and diagnosis","volume":"7","author":"Strydom","year":"2010","journal-title":"J Pol Pract Intellect Disabil"},{"key":"10.1016\/j.sapharm.2020.03.009_bib71","first-page":"163","article-title":"Core outcome sets","author":"Webbe","year":"2017","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1007-9","article-title":"International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy","volume":"16","author":"Beuscart","year":"2018","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.sapharm.2020.03.009_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1179\/2047387714Y.0000000061","article-title":"Building quality indicators for medication use in people aging with intellectual disabilities and behaviour disorders","volume":"62","author":"Flood","year":"2015","journal-title":"Int J Dev Disabil"},{"key":"10.1016\/j.sapharm.2020.03.009_bib74","first-page":"1","article-title":"Effectiveness of medication reviews in identifying and reducing medication-related problems among people with intellectual disabilities: a systematic review","author":"Nabhanizadeh","year":"2018","journal-title":"J Appl Res Intellect Disabil. 2019"},{"issue":"6","key":"10.1016\/j.sapharm.2020.03.009_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3750","article-title":"Association of focused medication review with optimization of psychotropic drug prescribing","volume":"1","author":"Sheehan","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.sapharm.2020.03.009_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003154","article-title":"Pharmacist intervention for glycaemic control in the community (the RxING study)","volume":"3","author":"Al Hamarneh","year":"2013","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.sapharm.2020.03.009_bib77","first-page":"493","article-title":"Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials","volume":"22","author":"Pousinho","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"24","key":"10.1016\/j.sapharm.2020.03.009_bib78","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.jacc.2016.03.528","article-title":"The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial","volume":"67","author":"Tsuyuki","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1715163519828318","article-title":"The evolution of pharmacy practice research\u2014Part I: time to implement the evidence","volume":"152","author":"Tsuyuki","year":"2019","journal-title":"Can Pharm J"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2788.2005.00636.x","article-title":"Social outcomes in adulthood of children with intellectual impairment: evidence from a birth cohort","volume":"49","author":"Hall","year":"2005","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1468-3156.2001.00108.x","article-title":"Patient information leaflets for people with learning disabilities who take psychiatric medication","volume":"29","author":"Strydom","year":"2001","journal-title":"Br J Learn Disabil"},{"issue":"12","key":"10.1016\/j.sapharm.2020.03.009_bib82","first-page":"521","article-title":"Geiwitz Allen - a pharmacy student clinical rotation program in a mental retardation facility.pdf","volume":"10","author":"Geiwitz","year":"1975","journal-title":"Hosp Pharm"},{"issue":"3","key":"10.1016\/j.sapharm.2020.03.009_bib83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cptl.2010.04.008","article-title":"A student practice experience focusing on the intellectually disabled","volume":"2","author":"Brahm","year":"2010","journal-title":"Curr Pharm Teach Learn"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib84","article-title":"Continuing education meetings and workshops: effects on professional practice and health care outcomes","author":"O'Brien","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.sapharm.2020.03.009_bib85","first-page":"13895","article-title":"Effectiveness of the spaced education pedagogy for clinicians' continuing professional development: a systematic review","author":"Phillips","year":"2019","journal-title":"Med Educ"},{"issue":"2","key":"10.1016\/j.sapharm.2020.03.009_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1017\/S2045796016000767","article-title":"From the EBM pyramid to the Greek temple: a new conceptual approach to Guidelines as implementation tools in mental health","volume":"26","author":"Salvador-Carulla","year":"2017","journal-title":"Epidemiol Psychiatr Sci"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174111930717X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174111930717X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:21:19Z","timestamp":1761556879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155174111930717X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S155174111930717X"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2020.03.009","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacist interventions for persons with intellectual disabilities: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}